58 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
98
Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.
Actelion Pharmaceuticals
38
Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers.
Actelion Pharmaceuticals
65
Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.
Actelion Pharmaceuticals
25
Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines.
Actelion Pharmaceuticals
19
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
Actelion Pharmaceuticals
29
Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
Actelion Pharmaceuticals
49
Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation.
Actelion Pharmaceuticals
58
Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.
Actelion Pharmaceuticals
1
Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.
Actelion Pharmaceuticals
35
Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Actelion Pharmaceuticals
23
Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
Actelion Pharmaceuticals
34
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.
Actelion Pharmaceuticals
27
Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.
Actelion Pharmaceuticals
25
Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.
Actelion Pharmaceuticals
3
Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.
Actelion Pharmaceuticals
59
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Actelion Pharmaceuticals
67
Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.
Actelion Pharmaceuticals
53
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Actelion Pharmaceuticals
30
Piperidine-based renin inhibitors: upper chain optimization.
Actelion Pharmaceuticals
34
Design and optimization of new piperidines as renin inhibitors.
Actelion Pharmaceuticals
69
2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.
Actelion Pharmaceuticals
15
Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists.
Actelion Pharmaceuticals
18
New classes of potent and bioavailable human renin inhibitors.
Actelion Pharmaceuticals
37
N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists.
Actelion Pharmaceuticals
100
Biomedical application of orexin/hypocretin receptor ligands in neuroscience.
Actelion Pharmaceuticals
103
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Actelion Pharmaceuticals
57
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
Actelion Pharmaceuticals
77
From bosentan (Tracleer ) to macitentan (Opsumit ): The medicinal chemistry perspective.
Actelion Pharmaceuticals
54
Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines.
Actelion Pharmaceuticals
54
Novel S1P(1) receptor agonists--part 2: from bicyclo[3.1.0]hexane-fused thiophenes to isobutyl substituted thiophenes.
Actelion Pharmaceuticals
3
Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity against Gram-Negative Bacteria.
Actelion Pharmaceuticals
40
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
Actelion Pharmaceuticals
163
PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS
Actelion Pharmaceuticals
485
PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS
Actelion Pharmaceuticals
95
Indole carboxamide derivatives as P2X7 receptor antagonists
Actelion Pharmaceuticals
565
Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
Actelion Pharmaceuticals
498
1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
Actelion Pharmaceuticals
86
Heterocyclic amide derivatives as P2X7 receptor antagonists
Actelion Pharmaceuticals
135
Azetidine amide derivatives as orexin receptor antagonists
Actelion Pharmaceuticals
16
Heterocyclic amide derivatives as P2X7 receptor antagonists
Actelion Pharmaceuticals
75
Heterocyclic amide derivatives as P2X7 receptor antagonists
Actelion Pharmaceuticals
15
Hydroxylated aminotriazole derivatives as ALX receptor agonists
Actelion Pharmaceuticals
145
Pyrazole and imidazole derivatives useful as orexin antagonists
Actelion Pharmaceuticals
243
4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
Actelion Pharmaceuticals
432
Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
Actelion Pharmaceuticals
464
Lactam derivatives useful as orexin receptor antagonists
Actelion Pharmaceuticals
152
Heterocyclic amide derivatives as P2X7 receptor antagonists
Actelion Pharmaceuticals
120
1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
Actelion Pharmaceuticals
198
2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
Actelion Pharmaceuticals
51
7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
Actelion Pharmaceuticals
59
Proline sulfonamide derivatives as orexin receptor antagonists
Actelion Pharmaceuticals
56
3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
Actelion Pharmaceuticals